GREENVILLE, South Carolina, June 09, 2026 (GLOBE NEWSWIRE) -- ARCpoint Inc. (TSXV: ARC) (the “Company” or “ARCpoint”) announces that its Board of Directors has appointed Peter Kendall as Interim Chief Executive Officer of the Company, effective June 9, 2026. Mr. Kendall’s appointment remains subject to acceptance by the TSX Venture Exchange (the “TSXV” or the “Exchange”), including acceptance of the Exchange’s required Personal Information Form and completion of customary Exchange review and verification procedures.
GUANGZHOU, China, June 09, 2026 (GLOBE NEWSWIRE) -- EHang Holdings Limited (Nasdaq: EH) (“EHang” or the “Company”), the world’s leading advanced air mobility (“AAM”) technology platform company, today announced its unaudited financial results for the first quarter ended March 31, 2026.
ZURICH, June 07, 2026 (GLOBE NEWSWIRE) -- The cryptocurrency market is witnessing a massive convergence of artificial intelligence and digital culture. Investors are shifting capital toward functional crypto ecosystems. Memecoins have evolved far beyond basic internet jokes.
BAYONNE, N.J., June 05, 2026 (GLOBE NEWSWIRE) -- BCB Bancorp, Inc. (the “Company”), (NASDAQ: BCBP), the holding company for BCB Community Bank (the “Bank”), today announced that, as previously reported on its Form 8-K filed on June 1, 2026, effective as of the close of trading on June 5, 2026, the Company granted 709,220 shares of restricted common stock, in accordance with Nasdaq Listing Rule 5635(c)(4), to Thomas M. O’Brien as an inducement material to Mr. O’Brien entering into an employment agreement with the Company and commencing employment as its Chief Executive Officer and President. Twenty percent of the shares of restricted stock will vest on each of December 31, 2026, December 31, 2027, December 31, 2028, December 31, 2029 and December 31, 2030, subject to Mr. O’Brien’s continued service with the Bank through each such vesting date, except that in certain circumstances described in the award, the restricted stock will vest in full.
BEDFORD, Mass., June 05, 2026 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global leader in the osteoarthritis pain management and regenerative solutions spaces focused on early intervention orthopedics, today announced that on June 1, 2026, Anika granted restricted stock units (“RSUs”) covering an aggregate of 3,360 shares of common stock to one newly hired non-executive employee. The grant was made pursuant to the Anika Therapeutics, Inc. 2021 Inducement Plan, as amended, was approved by the compensation committee of the board of directors pursuant to a delegation of authority by the board of directors, and, in accordance with Nasdaq Listing Rule 5635(c)(4), was made as a material inducement to the grantee’s acceptance of employment with Anika as a component of the grantee’s employment compensation.
SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, June 05, 2026 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq:ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced that on June 1, 2026 (the “Grant Date”), ORIC granted a total of 34,800 non-qualified stock options and 5,900 restricted stock units to two new non-executive employees who began their employment with ORIC in May 2026.
CAMBRIDGE, Mass., June 05, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (Nasdaq: NTLA), a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing and other core technologies, today announced that on June 1, 2026, it awarded inducement grants to six new employees under Intellia’s 2024 Inducement Plan, as amended, as a material inducement to employment.
SACRAMENTO, Calif., June 05, 2026 (GLOBE NEWSWIRE) -- The intersection of artificial intelligence and blockchain technology is entering a critical maturation phase, where speculative narratives are increasingly being replaced by projects that prioritize tangible network infrastructure. Solana Unchained stands at the forefront of this shift, constructing a decentralized environment where native tokens are not merely held for appreciation, but are required to power essential software utilities.
DALLAS, June 05, 2026 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA) (Taysha or the Company), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases of the central nervous system (CNS), today announced that, on June 1, 2026, the Compensation Committee of Taysha's Board of Directors granted four new employees, in the aggregate, restricted stock units (RSUs) representing 714,700 shares of the Company’s common stock and an option to purchase 468,600 shares of the Company's common stock in connection with their employment. The RSUs and stock option were granted under the Taysha Gene Therapies, Inc. 2023 Inducement Plan as an inducement material to the individuals entering employment with Taysha in accordance with Nasdaq Listing Rule 5635(c)(4).
Liven AS (Liven) disposed of a total of 1,900 Liven shares to its employees on 2 June 2026 under the 2024–2027 share option programme (Programme) at a price of EUR 3.71 per share. The ongoing Programme was approved by Liven’s annual general meeting on 19 April 2024, and the transaction price was agreed based on the latest available market price, the closing price on 1 June 2026.